|Articles|November 1, 2009

Research points to expanding role of botulinum toxin

Author(s)Philip M. Hanno, MD, MPH

In this podcast, Dr. Phil Hanno interviews Dr. Michael Chancellor on the potential role of botulinum toxin in urology.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

PSMA-targeted CD28 bispecific enters phase 1 trial in mCRPC

ByHannah Clarke

September 14th 2026

Andrew Peterson, MD, discusses advances in artificial urinary sphincter technology

ByAndrew C. Peterson, MD, MPH

September 14th 2026

Alternative BCG strains may help address ongoing supply challenges in NMIBC

ByEugene B. Cone, MD

September 11th 2026

Prior auth, step therapy, and consolidation pressure: Independent urology's challenge

ByCeleste Kirschner, CAE, MHSA

September 11th 2026

Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA

ByAmy M. Pearlman, MD,Karen Bigman, MBA

September 11th 2026

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Managing BPH Before Prostate Radiotherapy: Options Compared

Patient Selection and Partnership in Prostate Radiotherapy Spacing

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Alternative BCG strains may help address ongoing supply challenges in NMIBC

Doublet or triplet? Urologists weighs in on mCSPC options